{"id":7279,"date":"2025-06-02T12:00:48","date_gmt":"2025-06-02T10:00:48","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&p=7279"},"modified":"2025-05-30T12:13:18","modified_gmt":"2025-05-30T10:13:18","slug":"a-first-in-human-phase-1a-b-dose-escalation-expansion-study-of-bg-68501-a-selective-cdk2-inhibitor-as-monotherapy-or-in-combination-with-fulvestrant-for-patients-with-hr-her2-breast-cancer-and-o","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7279\/a-first-in-human-phase-1a-b-dose-escalation-expansion-study-of-bg-68501-a-selective-cdk2-inhibitor-as-monotherapy-or-in-combination-with-fulvestrant-for-patients-with-hr-her2-breast-cancer-and-o\/","title":{"rendered":"A first-in-human, phase 1a\/b, dose-escalation\/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+\/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data"},"content":{"rendered":"","protected":false},"template":"","post-tag":[812,705,819,822,719,813,775,820,815,821,814,818,784,811,816,817,46],"class_list":["post-7279","congress-resource","type-congress-resource","status-publish","hentry","post-tag-a-selective-cdk2-inhibitor","post-tag-asco","post-tag-bc","post-tag-bg-68501","post-tag-breast-cancer","post-tag-cdk2","post-tag-combination-therapy","post-tag-dose-escalation","post-tag-estrogen-receptor-antagonist","post-tag-first-in-human-study","post-tag-fulvestrant","post-tag-hr-her2-bc","post-tag-monotherapy","post-tag-phase-1a-b","post-tag-selective-estrogen-receptor-degrader","post-tag-serd","post-tag-solid-tumor","congress_resource_type-poster","content_type-reading","disease_state-breast-cancer","molecule-bg-68501"],"acf":{"congress_resource_url_override":"","congress":6816,"category":245,"prioritization":0,"key_data_presentation":false,"key_data_presentation_only":false,"key_data_presentation_prioritization":0,"tags":[811,812,813,814,815,816,817,784,775,818,819,719,820,821],"visible_tags":[705,46,822],"content-type":246,"summary":"","text_app":"","text":"","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":false,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/05\/Joshi_ASCO-2025_BG-68501-Poster.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"https:\/\/online.fliphtml5.com\/elkzy\/iqfk\/","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"","congress_resource_cta_link":"","authors":[7282],"field_page_schema_override":null},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/7282"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6816"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/822"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/46"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/705"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/821"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/820"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/719"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/819"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/818"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/775"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/784"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/817"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/816"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/815"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/814"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/813"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/812"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/811"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7279"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}